相关实验视频
Updated: Jun 11, 2025

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
18.8K
在密集血液治疗期间观察到严重高血糖的高频率:使用持续葡萄糖监测的前性研究
Marieke Tienstra1, Janneke W de Boer1, Jaap A van Doesum1
1Department of Hematology, University of Groningen, University Medical Center, Groningen, the Netherlands.
概括
持续血糖监测 (CGM) 能够有效地检测到密集血液治疗患者的高血糖症,通常是没有糖尿病的患者. 通过CGM进行早期检测可能会改善患者的治疗结果,并减少住院时间.
科学领域:
- 血液学 血液学 血液学
- 内分泌学 在内分泌学.
- 医疗技术 医疗技术 医学技术
背景情况:
- 密集的血液治疗包括化疗和干细胞移植等治疗.
- 这些治疗,结合生理压力,可以导致失糖症 (血糖水平异常).
- 低血糖与这些脆弱患者的不良临床结果有关.
研究的目的:
- 调查持续血糖监测 (CGM) 对于识别失糖症的有用性.
- 评估在接受密集血液护理的患者中高血糖的患病率和影响.
主要方法:
- 一项前性研究,涉及60名接受仿真抗原受体T细胞治疗或干细胞移植的患者.
- 同时使用CGM和点照顾 (POC) 血糖测量进行血糖监测.
- 分析葡萄糖水平,检测时间和与住院住院的相关性.
主要成果:
- 93%的患者患有高血糖,90%的患者以前没有糖尿病史.
- 严重的高血糖 (>13.1 mmol/L) 在38%的患者中发生.
- CGM检测到高血糖明显早于POC测量,并与长时间住院有关.
结论:
- 在密集的血液护理中,CGM是一种可行的和有价值的工具,用于早期和更好的检测高血糖症.
- 需要进一步的研究来探索CGM在优化葡萄糖管理和改善患者治疗结果方面的作用.
- 这些发现强调了在这种高风险人群中需要主动监测葡萄糖的必要性.
相关概念视频
Hypoglycemia and Glucagon
206
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
206
Diabetes: Symptoms, Diagnosis, and Complications
515
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
515
Diabetes: Management and Pharmacotherapy
243
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
243
Diabetes Mellitus: Type 2 and Gestational
2.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.2K
Diabetes Mellitus: Overview and Type I Subtype
2.5K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.5K
Insulin: Dosing Regimen and Adverse Effects
155
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
155

